CA3045455A1 - Methods of administering anti-fibrotic therapy - Google Patents

Methods of administering anti-fibrotic therapy Download PDF

Info

Publication number
CA3045455A1
CA3045455A1 CA3045455A CA3045455A CA3045455A1 CA 3045455 A1 CA3045455 A1 CA 3045455A1 CA 3045455 A CA3045455 A CA 3045455A CA 3045455 A CA3045455 A CA 3045455A CA 3045455 A1 CA3045455 A1 CA 3045455A1
Authority
CA
Canada
Prior art keywords
compound
subject
food
ppi
increase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3045455A
Other languages
English (en)
French (fr)
Inventor
Lin Pan
Dorothy Sze-Wing Cheung
Jeffrey Mark HARRIS
Indiana STROMBOM
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Priority to CA3247781A priority Critical patent/CA3247781A1/en
Publication of CA3045455A1 publication Critical patent/CA3045455A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA3045455A 2016-11-30 2017-11-29 Methods of administering anti-fibrotic therapy Pending CA3045455A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3247781A CA3247781A1 (en) 2016-11-30 2017-11-29 METHODS OF ADMINISTRATING ANTIFIBROTIC THERAPY

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662428163P 2016-11-30 2016-11-30
US62/428,163 2016-11-30
US201662432425P 2016-12-09 2016-12-09
US62/432,425 2016-12-09
PCT/US2017/063549 WO2018102323A1 (en) 2016-11-30 2017-11-29 Methods of administering anti-fibrotic therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3247781A Division CA3247781A1 (en) 2016-11-30 2017-11-29 METHODS OF ADMINISTRATING ANTIFIBROTIC THERAPY

Publications (1)

Publication Number Publication Date
CA3045455A1 true CA3045455A1 (en) 2018-06-07

Family

ID=60655162

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3045455A Pending CA3045455A1 (en) 2016-11-30 2017-11-29 Methods of administering anti-fibrotic therapy
CA3247781A Pending CA3247781A1 (en) 2016-11-30 2017-11-29 METHODS OF ADMINISTRATING ANTIFIBROTIC THERAPY

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3247781A Pending CA3247781A1 (en) 2016-11-30 2017-11-29 METHODS OF ADMINISTRATING ANTIFIBROTIC THERAPY

Country Status (11)

Country Link
US (3) US11207304B2 (enExample)
EP (2) EP3548025A1 (enExample)
JP (3) JP2020502054A (enExample)
KR (3) KR20230129628A (enExample)
CN (1) CN110087651A (enExample)
AU (3) AU2017366881A1 (enExample)
CA (2) CA3045455A1 (enExample)
IL (3) IL299447A (enExample)
MX (3) MX2019006143A (enExample)
TW (3) TWI891129B (enExample)
WO (1) WO2018102323A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI891129B (zh) 2016-11-30 2025-07-21 美商基因科技公司 投與抗纖維化療法之方法
CN114129517A (zh) * 2020-09-03 2022-03-04 苏州爱科百发生物医药技术有限公司 一种ak3287制剂及其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR092742A1 (es) * 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
RU2692485C2 (ru) * 2014-04-02 2019-06-25 Интермьюн, Инк. Противофиброзные пиридиноны
TWI891129B (zh) 2016-11-30 2025-07-21 美商基因科技公司 投與抗纖維化療法之方法

Also Published As

Publication number Publication date
EP4470624A3 (en) 2025-01-08
AU2025238129A1 (en) 2025-10-23
AU2017366881A1 (en) 2019-05-30
EP4470624A2 (en) 2024-12-04
KR20220139450A (ko) 2022-10-14
WO2018102323A1 (en) 2018-06-07
TW201825093A (zh) 2018-07-16
JP2020502054A (ja) 2020-01-23
AU2023263548B2 (en) 2025-10-16
US20240197693A1 (en) 2024-06-20
TW202539656A (zh) 2025-10-16
IL289544A (en) 2022-03-01
AU2023263548A1 (en) 2023-11-30
TWI891129B (zh) 2025-07-21
IL289544B2 (en) 2023-06-01
TWI826361B (zh) 2023-12-21
JP2022058873A (ja) 2022-04-12
TW202412795A (zh) 2024-04-01
MX2020011766A (es) 2020-11-24
US11925624B2 (en) 2024-03-12
US11207304B2 (en) 2021-12-28
IL266480A (en) 2019-07-31
KR20190089862A (ko) 2019-07-31
CN110087651A (zh) 2019-08-02
JP7495951B2 (ja) 2024-06-05
US12310951B2 (en) 2025-05-27
KR20230129628A (ko) 2023-09-08
CA3247781A1 (en) 2025-07-09
IL299447A (en) 2023-02-01
US20190321344A1 (en) 2019-10-24
US20220184046A1 (en) 2022-06-16
KR102575344B1 (ko) 2023-09-06
MX2023003924A (es) 2023-04-26
JP2023139157A (ja) 2023-10-03
MX2019006143A (es) 2019-10-17
EP3548025A1 (en) 2019-10-09

Similar Documents

Publication Publication Date Title
US12310951B2 (en) Methods of administering anti-fibrotic therapy
EP4349369B1 (en) Increasing drug bioavailability in naltrexone therapy
US20220105087A1 (en) Increasing Drug Bioavailability In Naltrexone Therapy
HK40012787A (en) Methods of administering anti-fibrotic therapy
TH27518A (th) รูปขนาดใช้ยาของซิสแอไบรด์ที่เป็นของแข็งไม่ขึ้นกับพีเอช ซึ่งปลดปล่อยได้ทันที

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220712

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20241003

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251111

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260106

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260227